Home Companies NOVO-B.CO
Healthcare · Drug Manufacturers - General · Peer Analysis

Novo Nordisk A/S (NOVO-B.CO) — Structural Peer Analysis

Novo Nordisk A/S ranks in the top quartile of its peer group, with stability as the main structural constraint. Trend conditions have deteriorated, without yet reaching an extreme downside state. Price action is not yet fully confirming the underlying structural profile.

Updated 2026-07-05 · STOXX600
ENTRY TODAY
Lower price zonebelow norm
TODAY (5y history)25th pct today
0th50th100th
Today the stock sits in a historically lower range and its multiple is below its own norm.
Describes where today's entry sits in the stock's own long-term price and valuation history. Descriptive only. Not investment advice.
Dimension Profile

Peer-relative scores, weakest to strongest

Weakest Stability 44
Around median
Weak Valuation 86
Top 10% of peers
Moderate Profitability 92
Top 10% of peers
Strongest Growth 94
Top 10% of peers
Peer-Relative Score
81
Peer-Score
Strong peer position
Signal qualityMedium
Structural Read

Premium Pricing Hinges on GLP-1 Narrative

Novo Nordisk A/S develops pharmaceutical products with a focus on diabetes and weight-loss therapies. The company is a leading player in the GLP-1 treatment segment.

Novo Nordisk is priced as a structural GLP-1 winner, with the market attaching a premium that reflects heightened sensitivity to any sign of volatility—1Y volatility stands at 38.5%, well above the pharma peer median. Each quarter is interpreted as confirmation of leadership, as the company delivers a sector-leading 44.7% operating margin with its GLP-1 portfolio. This focus on GLP-1 therapies, supported by a strong brand and global scale, reduces peer-relative weaknesses in the share price. The market prices in ongoing dominance and discounts peer risks. A break in the GLP-1 narrative or a major competitive move would likely trigger sharp repricing.

AssetNext · 2026-06-07 · Rule-based and descriptive. Not investment advice.

Explore how NOVO-B.CO compares across its peer group

Break down NOVO-B.CO's position across all dimensions with the full interactive tool.

Open full peer comparison →
Compare NOVO-B.CO with peers

This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.